A Review of the 2008 Singapore Ministry of Health Clinical Practice Guidelines on Osteoporosis and an Update


  • Chionh Siok Bee Department of Endocrinology, National University Hospital, Singapore
  • Manju Chandran Osteoporosis and Bone Metabolism Unit, Department of Endocrinology, Singapore General Hospital, Singapore


Osteoporosis is a major public health problem worldwide and it is of particular significance in a rapidly aging society such as Singapore. In order to prevent the devastating sequelae of osteoporosis, it is important, to diagnose the condition early, to identify its associated risk factors and to initiate pharmacotherapy promptly when required. In addition, it is important to increase awareness of this condition amongst both health care professionals and the public. The Singapore Ministry of Health (MOH) Clinical Practice Guidelines published in 2008 was an update of a previously published version in 2002. It aimed at providing the best evidence-based recommendations for diagnosis, classification, evaluation and multidisciplinary management of osteoporosis and osteoporotic fractures in Singapore. This article summarizes the guidelines, discusses their applicability and utilization in Singapore and briefly outlines updates in management since the publication of the CPG.


Download data is not yet available.


Committee on Ageing Issues: Report on Aging Population. 2006.

Lau EM. Epidemiology of osteoporosis. Best Pract Res Clin Rheumatol 2001;15(3):335-344.

Koh LK, Saw SM, Lee JJ, Leong KH, Lee J, National Working Committee on Osteoporosis, et al. Hip fracture incidence rates in Singapore 1991-1998. Osteoporos Int 2001;12(4):311-318.

Thoo FL, Chng SM, Lam KS, Lee JBI, Tan MC, Teh HS, et al. To establish the normal bone mineral density reference database for the Singapore male. Ann Acad Med Singapore 2002;31(1):21-25.

Leong KH, Feng PH. Bone mineral density measurements using the Hologic QD2000 in 175 Singaporean women aged 20-80. Singapore Med J 1997;38(1):25-26.

Koh LK, Sedrine WB, Torralba TP, Kung A, Fujiwara S, Chan SP, et al. A simple tool to identify Asian women at increased risk of osteoporosis. Osteoporos Int 2001;12(8):699-705.

Ho SC, Leung PC, Swaminathan R, Chan C, Chan SS, Fan YK, et al. Determinants of bone mass in Chinese women aged 21-40 years. II. Pattern of dietary calcium intake and association with bone mineral density. Osteoporos Int 1994;4(3):167-175.

Chan HH, Lau EM, Woo J, Lin F, Sham A, Leung PC, et al. Dietary calcium intake physical activity and the risk of vertebral fracture in Chinese. Osteoporos Int 1996;6(3):228-232.

Cumming RG, Nevitt MC. Calcium for prevention of osteoporotic fractures in postmenopausal women. J Bone Miner Res 1997;12(9):1321-1329.

Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci ED, Dietrich T, -Hughes BD, et al. Fracture prevention with vitamin D supplementation a meta-analysis of randomized controlle d trials. JAMA 2005;293(18):2257-2264.

Bischoff-Ferrari HA, -Hughes BD, Willett WC, Staehelin HB, Bazemore MG, Zee RY, et al. Effect of Vitamin D on falls a meta-analysis. JAMA 2004;291(16):1999-2006.

Shea B, Bonaiuti D, Iovine R, Negrini S, Robinson V, Kemper HC, et al. Cochrane Review on exercise for preventing and treating osteoporosis in postmenopausal women. Eura Medicophys 2004;40(3):199-209.

Englund U, Littbrand H, Sondell A, Pettersson U, Bucht G. A 1-year combined weight-bearing training program is beneficial for bone mineral density and neuromuscular function in older women. Osteoporos Int 2005;16(9):1117-1123.

Daniell HW. Osteoporosis of the slender smoker. Vertebral compression fractures and loss of metacarpal cortex in relation to postmenopausal cigarette smoking and lack of obesity. Arch Intern Med 1976;136(3):298-304.

Hernandez-Avila M, Colditz GA, Stampfer MJ, Rosner B, Speizer FE, Willett WC, et al. Caffeine moderate alcohol intake and risk of fractures of the hip and forearm in middle-aged women. Am J Clin Nutr 1991;54(1):157-163.

Parker MJ, Gillespie WJ, Gillespie LD. Effectiveness of hip protectors for preventing hip fractures in elderly people systematic review. BMJ 2006;332(7541):571-574.

Sawka AM, Boulos P, Beattie K, Thabane L, Papaioannou A, Gafni A, et al. Do hip protectors decrease the risk of hip fracture in institutional and community-dwelling elderly? A systematic review and meta-analysis of randomized controlled trials. Osteoporos Int 2005;16(12):1461-1474.

Gillespie LD, Gillespie WJ, Robertson MC, Lamb SE, Cumming RG, Rowe BH, et al. Interventions for preventing falls in elderly people. Cochrane Database Syst Rev 2003;(4):CD000340.

Chang JT, Morton SC, Rubenstein LZ, Mojica WA, Maglione M, Suttorp MJ, et al. Interventions for the prevention of falls in older adults. Systematic review and meta-analysis of randomised clinical trials. BMJ Clinical research ed.) 2004;328(7441):680.

Nguyen ND, Frost SA, Center JR, Eisman JA, Nguyen TV. Development of a nomogram for individualizing hip fracture risk in men and women. Osteoporos Int 2007;18(8):1109-1117.

Kanis JA, Borgstrom F, De Laet C, Johansson H, Johnell O, Jonsson B, et al. Assessment of fracture risk. Osteoporos Int 2005;16(6):581-589.

Kung AWC, Lee KK, Ho AY, Tang G, Luk KD. Ten-year risk of osteoporotic fractures in postmenopausal Chinese women according to clinical risk factors and BMD T-scores: A prospective study. J Bone Miner Res 2007;22(7):1080-1087.

Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebralfractures. Fracture Intervention Trial Research Group. Lancet 1996;348(9041):1535-1541.

McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001 Feb 1;344(5):333-40.

Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356(18):1809-1822.

Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA.1999 Oct 13;282(14):1344-52.

Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, et al. Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab. 2000 Nov;85(11):4118-24.

Cramer JA, Gold DT, Silverman SL, Lewiecki EM. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 2007;18(8):1023-1031.

Chesnut IC, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004 Aug;19(8):1241-9.

Reginster JY, Adami S, Lakatos P, Greenwald M, Stepan JJ, Silverman SL, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis 2 year results from the MOBILE study. Ann Rheum Dis 2006;65(5):654-661.

Adami S, Felsenberg D, Christiansen C, Robinson J, Lorenc RS, Mahoney P, et al. Efficacy and safety of ibandronate given by intravenous injection once every 3 months. Bone 2004;34(5):881-889.

Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350(5):459-468.

Reginster JY, Seeman E, Vernejoul MCD, Adami S, Compston J, Phenekos C, et al. Strontium ranelate reduces the risk of non vertebral fractures in postmenopausal women with osteoporosis Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005;90(5):2816-2822.

Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282(7):637-645.

Chesnut CH, Silverman S, Andriano K, Genant H, Gimona A, Harris S, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000;109(4):267-276.

Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344(19):1434-1441.

Vahle JL, Long GG, Sandusky G, Westmore M, Ma YL, Sato M, et al. Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose. Toxicol Pathol 32(4):426-438.

Elliot-Gibson V, Bogoch ER, Jamal SA, Beaton DE. Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: A systematic review. Osteoporos Int. 2004;15(10):767-778.

Seeman E, Compston J, Adachi J, Brandi ML, Cooper C, Dawson-Hughes B, et al. Non-compliance the Achilles heel of anti-fracture efficacy. Osteoporos Int. 2007;18(6):711-719.

Leib ES, Lenchik L, Bilezikian JP, Maricic MLJ, Watts NLB. Position statements of the International Society for Clinical Densitometry: methodology. J Clin Densitom 2002;5 Suppl:S5-10.

Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 2000;85(1):231-236.

Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J. The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporosis Int 2000;11 Suppl 6:S2-17.

Seeman E, Bianchi G, Khosla S, Kanis JA, Orwoll E. Bone fragility in men-where are we? Osteoporos Int. 2006;17(11):1577-83.

Kanis JA, Johnell O, Oden A, Dawson A, De Laet C, Jonsson B. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int. 2001 Dec;12(12):989-95.

Ringe JD, Dorst A, Faber H, Ibach K. Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study. Rheumatol Int. 2004 Mar;24(2):110-3.

Ringe JD, Faber H, Farahmand P, Dorst A. Efficacy of risedronate in men with primary and secondary osteoporosis: Results of a 1-year study. Rheumatol Int. 2006 Mar;26(5):427-31.

Kaufman JM, Orwoll E, Goemaere S, San Martin J, Hossain A, Dalsky GP, et al. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: Treatment and discontinuation of therapy. Osteoporos Int. 2005 May;16(5):510-6.

van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid- induced osteoporosis: A meta-analysis. Osteoporos Int. 2002 Oct;13(10):777-87.

van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000 Jun;15(6):993-1000.

Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: A randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001;44(1):202-211.

Cohen S, Levy RM, Keller M, Boling E, Emkey RD, Greenwald M, et al. Risedronate therapy prevents corticosteroid-induced bone loss. A twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis and Rheumatism 1999;42(11):2309-2318.

Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest.1998 Oct 15;102(8):1627-33.

Cauley JA, El-Hajj Fuleihan G, Arabi A, Fujiwara S, Ragi-Eis S, Calderon A, et al. Official Positions for FRAX® clinical regarding international differences from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®. J Clin Densitom 2011;14(3):240-262.

Hans DB, Kanis JA, Baim S, Bilezikian JP, Binkley N, Cauley JA, et al. Joint Official Positions of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX(®). Executive Summary of the 2010 Position Development Conference on Interpretation and use of FRAX® in clinical practice. J Clin Densitom 2011;14(3):171-180.

Lippuner K, Johansson H, Borgström F, Kanis JA, Rizzoli R. Cost-effective intervention thresholds against osteoporotic fractures based on FRAX® in Switzerland. Osteoporos Int 2012; Jan 6 (Epub ahead of print)

Johansson H, Kanis JA, McCloskey EV, Odén A, Devogelaer JP, Kaufman JM, et al. A FRAX® model for the assessment of fracture probability in Belgium. Osteoporos Int 2011;22(2):453-461.

Kanis JA, Johansson H, Odén A, McCloskey EV. The distribution of FRAX(®)-based probabilities in women from Japan. J Bone Miner Metab 2012; Aug 22 (Epub ahead of print).

Chee Kwang Yung, Stephanie Fook-Chong, Manju Chandran. The prevalence of recognized contributors to secondary osteoporosis in South East Asian men and post-menopausal women. Are Z score diagnostic thresholds useful predictors of their presence? Arch Osteoporos 2012 DOI10.1007/s11657-012-0078-z.

Bolland MJ, Barber PA, Doughty RN, Mason B, Horne A, Ames R, et al. Vascular events in healthy older women receiving calcium supplementation: Randomised controlled trial. BMJ 2008;336(7638):262-266.

Bolland MJ, Grey A, Avenell A, Gamble GD, Reid IR. Calcium supplements with or without vitamin D and risk of cardiovascular events: Reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. BMJ 2011;342:d2040.

Bolland MJ, Avenell A, Baron JA, Grey A, MacLennan GS, Gamble GD, et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: Meta-analysis. BMJ 2010;341:c3691.

Abrahamsen B, Sahota O. Do calcium plus vitamin D supplements increase cardiovascular risk? BMJ 2011;342:d2080.

Lewis JR, Calver J, Zhu K, Flicker L, Prince RL. Calcium supplementation and the risks of atherosclerotic vascular disease in older women: Results of a 5-year RCT and a 4.5-year follow-up. J Bone Miner Res 2011;26(1):35-41.

Li K, Kaaks R, Linseisen J, Rohrmann S. Associations of dietary calcium intake and calcium supplementation with myocardial infarction and stroke risk and overall cardiovascular mortality in the Heidelberg cohort of the European Prospective Investigation into Cancer and Nutrition study (EPIC-Heidelberg). Heart 2012;98(12):920-925.

Nordin BEC, Lewis JR, Daly RM, Horowitz J, Metcalfe A, Lange K, et al. The calcium scare-what would Austin Bradford Hill have thought? Osteoporos Int 2011;22(12):3073-3077.

Lee YHD, Lim YW, Ling PS, Tan YY, Cheong M, Lam KS, et al. Inadequate dietary calcium intake in elderly patients with hip fractures. Singapore Med J 2007;48(12):1117-1121.

Zittermann A, Pilz S, Börgermann J, Gummert JF. Calcium supplementation and vitamin D: A trigger for adverse cardiovascular events? Future cardiology 2011;7(6):725-727.

Lips P, Duong T, Oleksik A, Black D, Cummings S, Cox D, et al. A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: Baseline data from the multiple outcomes of raloxifene evaluation clinical trial. J Clin Endocrinol Metab 2001;86(3):1212-1221.

Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: What clinicians need to know. J Clin Endocrinol Metab 2011;96(1):53-58.

Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment, and prevention of vitamin D deficiency: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011;96(7):1911-1930.

Gutiérrez OM, Farwell WR, Kermah D, Taylor EN. Racial differences in the relationship between vitamin D, bone mineral density, and parathyroid hormone in the National Health and Nutrition Examination Survey. Osteoporos Int 2011;22(6):1745-1753.

Chandran M, Hoeck HC, Wong HC, Zhang RF, Dimai HP. Vitamin D status and its relationship with bone mineral density and parathyroid hormone in Southeast Asian adults with low bone density. Endocr Pract 2011;17(2):226-234.

Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci ED, Dietrich T, -Hughes BD, et al. Fracture prevention with vitamin D supplementation, a meta-analysis of randomized controlled trials. JAMA 2005;293(18):2257-2264.

Bischoff-Ferrari HA, Willett WC, Orav EJ, Oray EJ, Lips P, Meunier PJ, et al. A pooled analysis of vitamin D dose requirements for fracture prevention. N Engl J Med 2012;367(1):40-49.

Grant AM, Avenell A, Campbell MK, McDonald AM, MacLennan GS, McPherson GC, et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial. Lancet 2005;365(9471):1621-1628.

Jackson RD, LaCroix AZ, Gass M, Wallace RB, Robbins J, Lewis CE, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006;354(7):669-683.

Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361(8):756-765.

Reid IR, Miller PD, Brown JP, Kendler DL, Fahrleitner-Pammer A, Valter I, et al. Effects of denosumab on bone histomorphometry: The FREEDOM and STAND studies. J Bone Miner Res 2010;25(10):2256-2265.

Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, et al. Effects of continuing or stopping alendronate after 5 years of treatment: The Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006;296(24):2927-2938.

Mellström DD, Sörensen OH, Goemaere S, Roux C, Johnson TD, Chines AA, et al. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 2004;75(6):462-468.

Reginster JY, Bruyère O, Sawicki A, Roces-Varela A, Fardellone P, Roberts A, et al. Long-term treatment of postmenopausal osteoporosis with strontium ranelate: Results at 8 years. Bone 2009;45(6):1059-1064.

Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 2012;27(2):243-254.

Miller PD, Recker RR, Reginster JY, Riis BJ, Czerwinski E, Masanauskaite D, et al. Efficacy of monthly oral ibandronate is sustained over 5 years: The MOBILE long-term extension study. Osteoporos Int 2012;23(6):1747-1756.

Papapoulos S, Chapurlat R, Libanati C, Brandi ML, Brown JP, Czerwiński E, et al. Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension. J Bone Miner Res 2012;27(3):694-701.

Goh SK, Yang KY, Koh JSB, Wong MK, Chua SY, Chua DTC, et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: A caution. J Bone Joint Surg Br 2007;89(3):349-353.

Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, et al. Atypical subtrochanteric and diaphyseal femoral fractures report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010;25(11):2267-2294.

Rizzoli R, Akesson K, Bouxsein M, Kanis JA, Napoli N, Papapoulos S, et al. Subtrochanteric fractures after long-term treatment with bisphosphonates: A European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporos Int 2011;22(2):373-390.

Orwoll ES, Miller PD, Adachi JD, Brown J, Adler RA et al. Efficacy and safety of once-yearly i.v. infusion of zoledronic acid 5 mg versus once-weekly 70 mg oral alendronate in the treatment of male osteoporosis: A randomized, multicenter, double blind, active-controlled study. J Bone Miner Res 25:2239-2250.

Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C et al. Zoledronic acid in reducing clinical fracture and mortality after hip fracture. N Engl J Med 2007; 357:nihpa40967. DOI:10.1056/NEJMe074941.

Boonen S, Reginster JY, Kaufman JM, Lippuner K, Zanchetta J et al. Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med 2012; Nov; 367(18):1714-23.

Ringe JD, Dorst A and Farahmand P. Efficacy of strontium ranelate on bone mineral density in men with osteoporosis. Arzneimittelforschung 2010; 60:267-272.

Smith MR, Egerdie B and Toriz NH. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 361:756-765.

Orwoll E, Teglbjaerg CS, Langdahl BL, Chapurlat R, Czerwinski E et al. A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab 2012 Sep;97(9):3161-9.

Marsh D, Akesson K, Beaton DE, Bogoch ER, Boonen S, Brandi ML, et al. Coordinator-based systems for secondary prevention in fragility fracture patients. Osteoporos Int 2011;22(7):2051-2065.

Adler RA. Secondary fracture prevention. Curr Osteoporos Rep 2012;10(1):22-27.

Manju Chandran and Matthew Tan. Addressing the care gap in secondary fracture prevention in a South East Asian hospital-Effective initiation of osteoporosis diagnosis and treatment for patients with fragility fractures through “OPTIMAL”. Osteoporos Int 2012; 23(Suppl2) DOI10.1007/S00198-012-1923-7.

Daniela Korthoewer and Manju Chandran (On behalf of the Endocrine and Metabolic Society of Singapore). Osteoporosis management and the utilization of FRAX(R): Asurvey amongst health care professionals of the Asia-Pacific. Arch Osteoporosis 2012; DOI 10.1007/s11657-012-0097-9.

Hutchinson A, McIntosh A, Cox S, Gilbert C. Towards efficient guidelines. How to monitor guideline use in primary care. Health Technol Assess 2003; 7(iii):1-97.

Lee YH, Lim YW, Lam KS. Economic cost of osteoporotic hip fractures in Singapore. Singapore Medical Journal 2008;49(12):980-984.

Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, Silverman S. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: Relationship to vertebral and non vertebral fractures from 2 US claims databases. Mayo Clin Proc 2006; 81(8):1013-1022.

M.H.H Cheen, M.C. Kong, R.F Zhang, F.M.H Tee, M. Chandran. Adherence to osteoporosis medications amongst Singaporean patients. Osteoporos Int 2012; 23:1053-1060.

Solomon DH, Avorn J, Katz JN, Finkelstein JS, Arnold M, Polinski JM, Brookhart MA. Compliance with osteoporosis medications. Arch Intern Med 2005; 165(20):2414-2419.

Bocuzzi S, Foltz S, Omar M. Assessment of adherence and persistence with daily and weekly dosing regimens of oral bisphosphonates. Osteoporos Int 2005; 16:S35-S36.



How to Cite

Bee, C. S., & Chandran, M. (2014). A Review of the 2008 Singapore Ministry of Health Clinical Practice Guidelines on Osteoporosis and an Update. Journal of the ASEAN Federation of Endocrine Societies, 27(2), 159. Retrieved from https://asean-endocrinejournal.org/index.php/JAFES/article/view/31



Feature Articles